Cargando…
Final analysis of potential drug–drug interactions between highly purified cannabidiol and anti‐seizure medications in an open‐label expanded access program
OBJECTIVE: The aim of this study was to assess potential drug–drug interactions between highly purified cannabidiol (CBD) and anti‐seizure medications (ASMs). METHODS: Our group previously reported that in a sample of adults and children receiving CBD in an open‐label expanded access program, there...
Autores principales: | Gaston, Tyler E., Bebin, E. Martina, Cutter, Gary R., Grayson, Leslie, Szaflarski, Jerzy P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690661/ https://www.ncbi.nlm.nih.gov/pubmed/37593907 http://dx.doi.org/10.1002/epi4.12815 |
Ejemplares similares
-
Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment‐Resistant Epilepsy
por: Davis, Brittney H., et al.
Publicado: (2021) -
A preliminary study of the effects of cannabidiol (CBD) on brain structure in patients with epilepsy
por: Sharma, Ayushe A., et al.
Publicado: (2019) -
An interaction between warfarin and cannabidiol, a case report
por: Grayson, Leslie, et al.
Publicado: (2017) -
Long‐term safety and treatment effects of cannabidiol in children and adults with treatment‐resistant epilepsies: Expanded access program results
por: Szaflarski, Jerzy P., et al.
Publicado: (2018) -
Long‐term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open‐label extension trial
por: Thiele, Elizabeth A., et al.
Publicado: (2021)